Getinge AB (publ)

BATS-CHIXE:GETIBS Stock Report

Market Cap: SEK 49.2b

Getinge Valuation

Is GETIBS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GETIBS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GETIBS (SEK186.18) is trading below our estimate of fair value (SEK388.11)

Significantly Below Fair Value: GETIBS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GETIBS?

Key metric: As GETIBS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GETIBS. This is calculated by dividing GETIBS's market cap by their current earnings.
What is GETIBS's PE Ratio?
PE Ratio29.1x
EarningsSEK 1.69b
Market CapSEK 49.16b

Price to Earnings Ratio vs Peers

How does GETIBS's PE Ratio compare to its peers?

The above table shows the PE ratio for GETIBS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30.9x
SN. Smith & Nephew
35.3x22.5%UK£8.6b
NIOX NIOX Group
23.7x17.1%UK£260.3m
EKF EKF Diagnostics Holdings
24.4xn/aUK£116.6m
CTEC ConvaTec Group
40.4x20.5%UK£4.9b
GETIBS Getinge
29.1x22.0%SEK 49.2b

Price-To-Earnings vs Peers: GETIBS is good value based on its Price-To-Earnings Ratio (29.1x) compared to the peer average (30.9x).

Price to Earnings Ratio vs Industry

How does GETIBS's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GETIBS is good value based on its Price-To-Earnings Ratio (29.1x) compared to the European Medical Equipment industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is GETIBS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GETIBS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.1x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate GETIBS's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GETIBS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 186.18
SEK 225.44
+21.1%
16.0%SEK 300.00SEK 180.00n/a9
Nov ’25SEK 196.55
SEK 225.44
+14.7%
16.0%SEK 300.00SEK 180.00n/a9
Oct ’25SEK 218.05
SEK 233.00
+6.9%
14.0%SEK 300.00SEK 190.00n/a8
Sep ’25n/a
SEK 230.00
0%
14.2%SEK 300.00SEK 190.00n/a8
Aug ’25SEK 208.30
SEK 230.00
+10.4%
14.2%SEK 300.00SEK 190.00n/a8
Jul ’25n/a
SEK 225.44
0%
15.8%SEK 290.00SEK 165.00n/a9
Jun ’25n/a
SEK 229.22
0%
13.2%SEK 300.00SEK 186.00n/a9
May ’25SEK 229.50
SEK 235.50
+2.6%
12.2%SEK 300.00SEK 186.00n/a10
Apr ’25n/a
SEK 226.10
0%
14.9%SEK 300.00SEK 164.00n/a10
Mar ’25n/a
SEK 227.10
0%
15.2%SEK 300.00SEK 164.00n/a10
Feb ’25n/a
SEK 236.60
0%
11.3%SEK 300.00SEK 210.00n/a10
Jan ’25n/a
SEK 228.56
0%
12.8%SEK 300.00SEK 190.00n/a9
Dec ’24n/a
SEK 220.33
0%
17.4%SEK 300.00SEK 150.00n/a9
Nov ’24n/a
SEK 210.89
0%
14.7%SEK 250.00SEK 150.00SEK 196.559
Oct ’24n/a
SEK 203.11
0%
16.1%SEK 250.00SEK 134.00SEK 218.059
Sep ’24SEK 186.55
SEK 203.11
+8.9%
16.1%SEK 250.00SEK 134.00n/a9
Aug ’24SEK 193.40
SEK 203.11
+5.0%
16.1%SEK 250.00SEK 134.00SEK 208.309
Jul ’24SEK 186.10
SEK 230.40
+23.8%
19.9%SEK 300.00SEK 139.00n/a10
Jun ’24SEK 246.70
SEK 265.30
+7.5%
11.8%SEK 300.00SEK 193.00n/a10
May ’24SEK 271.60
SEK 260.33
-4.1%
11.6%SEK 295.00SEK 193.00SEK 229.509
Apr ’24SEK 249.60
SEK 252.89
+1.3%
8.6%SEK 285.00SEK 208.00n/a9
Mar ’24SEK 223.70
SEK 253.44
+13.3%
8.1%SEK 285.00SEK 208.00n/a9
Feb ’24SEK 240.30
SEK 252.89
+5.2%
7.9%SEK 285.00SEK 208.00n/a9
Jan ’24SEK 213.70
SEK 264.33
+23.7%
5.5%SEK 285.00SEK 240.00n/a9
Dec ’23SEK 232.00
SEK 274.89
+18.5%
5.4%SEK 300.00SEK 250.00n/a9
Nov ’23SEK 224.00
SEK 273.63
+22.2%
5.5%SEK 300.00SEK 250.00n/a8

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Guerbet

€339.2m

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

0ELV

€27.00

7D

-9.8%

1Y

50.2%

Arjo

SEK 9.2b

Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.

0HQ8

SEK 33.92

7D

-4.8%

1Y

-9.6%

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

0HNZ

€18.06

7D

-6.1%

1Y

5.3%